Program
baricitinib
Also written as “Baricitinib”, “LY3009104” and “INCB028050”.
Its studies are mostly in Arthritis, Rheumatoid · Dermatitis, Atopic · Lupus Erythematosus, Systemic · COVID-19 · Arthritis, Juvenile, led by 5 companies.
Drug pageBaricitinib: every studyMany companies study it; this page follows only the 58 they lead. All 149 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 546 open or running | phase 4since Apr 12, 2019 | Aug 18, 2010 | Mar 2028phase 3 · NCT05723198 |
| Galvani Bioelectronicsits history only | 11 open or running | no phasesince Jul 5, 2021 | Jul 5, 2021 | Jul 2027NCT05003310 |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Aug 9, 2021 | Aug 9, 2021 | none ahead |
| Incepta Pharmaceuticalsits history only | 10 open or running | phase 3since Sep 20, 2021 | Sep 20, 2021 | none ahead |
| Incyteits history only | 10 open or running | phase 2since May 13, 2009 | May 13, 2009 | none ahead |
Also a collaborator on its studies: Q2 Solutions and Horus Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 37 studies since Aug 18, 2010.
- Oct 30, 2018Phase 3 study in Dermatitis, AtopicNCT03733301 · 329 enrolled · Argentina, Australia, Austria and more
- Nov 14, 2018Phase 2 study in Liver Cirrhosis, BiliaryNCT03742973 · 2 enrolled · United States, Puerto Rico
- Dec 11, 20182 phase 3 studies in Arthritis, JuvenileNCT03773978, NCT03773965
- Feb 14, 2019Phase 3 study in Lupus Erythematosus, SystemicNCT03843125 · 1,147 enrolled · United States, Argentina, Australia and more
- Apr 1, 2019Phase 3 study in Alopecia AreataNCT03899259 · 606 enrolled · United States, Argentina, Australia and more
- Apr 12, 2019Phase 4 study in Arthritis, RheumatoidNCT03915964 · 2,659 enrolled · United States, Australia, Austria and more
- May 15, 2019Phase 3 study in Dermatitis, AtopicNCT03952559 · 516 enrolled · Argentina, Australia, Austria and more
- Sep 10, 2019Phase 4 study in Arthritis, RheumatoidNCT04086745 · 1,050 enrolled · United States
- Sep 11, 20192 phase 3 studiesNCT04088409, NCT04088396
- Jun 5, 2020Phase 3 study in COVID-19NCT04421027 · 1,525 enrolled · United States, Argentina, Brazil and more
- Aug 17, 2020Phase 3 study in Nakajo syndromeNCT04517253 · 10 enrolled · Japan
- Oct 8, 2021Phase 3 study in COVID-19NCT05074420 · 6 enrolled · United States, Brazil, Mexico and more
- Feb 3, 2023Phase 3 study in AlopeciaNCT05723198 · 595 planned · United States, Argentina, Australia and more
- Oct 27, 20252 phase 3 studies in Diabetes Mellitus, Type 1NCT07222332, NCT07222137
Ahead
- Mar 2028Primary completion: phase 3 study in AlopeciaNCT05723198
- Jul 2028Primary completion: phase 3 study in Diabetes Mellitus, Type 1NCT07222332
- Jul 2031Primary completion: phase 3 study in Diabetes Mellitus, Type 1NCT07222137
- Jul 2031Primary completion: phase 3 study in Arthritis, JuvenileNCT03773965
TargetBeta
“An orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| jaktinibrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 31 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| momelotinibrule | GlaxoSmithKline | phase 3 | 17 |
Studies
All 54 Eli Lilly leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07222332Diabetes Mellitus, Type 1 · United States, Australia, Belgium and more | 3 | Recruiting | Jul 2028 | 300 |
| NCT07222137Diabetes Mellitus, Type 1 · United States, Australia, Belgium and more | 3 | Recruiting | Jul 2031 | 150 |
| NCT05723198Alopecia · United States, Argentina, Australia and more | 3 | Recruiting | Mar 2028 | 595 |
| NCT05074420COVID-19 · United States, Brazil, Mexico and more | 3 | Terminated | Sep 5, 2024 | 6 |
| NCT04517253Nakajo syndrome · Japan | 3 | Terminated | Apr 4, 2023 | 10 |
| NCT04421027COVID-19 · United States, Argentina, Brazil and more | 3 | Completed | Feb 12, 2021 | 1,525 |
| NCT04088409Uveitis · France, Germany, Italy and more | 3 | Active, not recruiting | Jul 17, 2023 | 30 |
| NCT04088396Arthritis, Juvenile · Argentina, Belgium, Brazil and more | 3 | Active, not recruiting | Oct 2026 | 58 |
| NCT04086745Arthritis, Rheumatoid · United States | 4 | Completed | May 19, 2025 | 1,050 |
| NCT03952559Dermatitis, Atopic · Argentina, Australia, Austria and more | 3 | Completed | Apr 24, 2022 | 516 |
| NCT03915964Arthritis, Rheumatoid · United States, Australia, Austria and more | 4 | Completed | May 28, 2025 | 2,659 |
| NCT03899259Alopecia Areata · United States, Argentina, Australia and more | 3 | Completed | Jan 24, 2021 | 606 |
| NCT03843125Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 3 | Terminated | Apr 1, 2022 | 1,147 |
| NCT03773978Arthritis, Juvenile · Argentina, Australia, Austria and more | 3 | Completed | Jan 26, 2022 | 220 |
| NCT03773965Arthritis, Juvenile · Argentina, Australia, Austria and more | 3 | Recruiting | Jul 2031 | 190 |
| NCT03742973Liver Cirrhosis, Biliary · United States, Puerto Rico | 2 | Terminated | Sep 26, 2019 | 2 |
| NCT03733301Dermatitis, Atopic · Argentina, Australia, Austria and more | 3 | Completed | Jul 29, 2019 | 329 |
| NCT03616964Lupus Erythematosus, Systemic · United States, Argentina, Chile and more | 3 | Completed | Sep 24, 2021 | 778 |
| NCT03616912Lupus Erythematosus, Systemic · United States, Australia, Austria and more | 3 | Terminated | Nov 1, 2021 | 830 |
| NCT03570749Alopecia Areata · United States, Japan, Mexico and more | 3 | Completed | Feb 2, 2021 | 784 |
| NCT03559270Dermatitis, Atopic · United States, Canada, Puerto Rico | 3 | Terminated | Oct 14, 2021 | 374 |
| NCT03435081Dermatitis, Atopic · United States, Canada, Puerto Rico | 3 | Completed | Dec 9, 2019 | 440 |
| NCT03428100Dermatitis, Atopic · Austria, Belgium, Brazil and more | 3 | Completed | Nov 25, 2019 | 463 |
| NCT03334435Dermatitis, Atopic · Argentina, Australia, Austria and more | 3 | Completed | Sep 21, 2020 | 1,645 |
| NCT03334422Dermatitis, Atopic · Argentina, Australia, Austria and more | 3 | Completed | Dec 12, 2018 | 615 |
| NCT03334396Dermatitis, Atopic · Czechia, Denmark, France and more | 3 | Completed | Dec 6, 2018 | 660 |
| NCT03212638Healthy · Singapore | 1 | Completed | Jul 31, 2017 | 42 |
| NCT02758613Healthy · China | 1 | Completed | Jul 2016 | 33 |
| NCT02708095Lupus Erythematosus, Systemic · United States, Argentina, Austria and more | 2 | Completed | Oct 12, 2017 | 314 |
| NCT02576938Dermatitis, Atopic · United States, Japan | 2 | Completed | Feb 2017 | 124 |
| NCT02340104Healthy Volunteers · United Kingdom | 1 | Completed | Feb 2015 | 8 |
| NCT02265705Arthritis, Rheumatoid · Argentina, Brazil, China | 3 | Completed | May 2017 | 290 |
| NCT02263911Healthy Participants · Japan | 1 | Completed | Dec 2014 | 16 |
| NCT01968057Healthy Volunteers · United Kingdom | 1 | Completed | Dec 2013 | 18 |
| NCT01937026Healthy Volunteers · United Kingdom | 1 | Completed | Nov 2013 | 18 |
| NCT01925144Healthy Volunteers · United Kingdom | 1 | Completed | Nov 2013 | 30 |
| NCT01924299Healthy Volunteers · United Kingdom | 1 | Completed | Nov 2013 | 36 |
| NCT01910311Healthy Volunteers · United Kingdom | 1 | Completed | Oct 2013 | 18 |
| NCT01896726Healthy Volunteers · United Kingdom | 1 | Completed | Oct 2013 | 20 |
| NCT01885078Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Nov 12, 2020 | 2,877 |
| NCT01870388Liver Diseases · United States | 1 | Completed | Jul 2013 | 16 |
| NCT01859078Healthy Volunteers · United Kingdom | 1 | Completed | Aug 2013 | 28 |
| NCT01721057Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Sep 2014 | 684 |
| NCT01721044Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Jun 2014 | 527 |
| NCT01711359Arthritis, Rheumatoid · United States, Argentina, Austria and more | 3 | Completed | Feb 2015 | 588 |
| NCT01710358Arthritis, Rheumatoid · United States, Argentina, Belgium and more | 3 | Completed | Mar 2015 | 1,307 |
| NCT01683409Diabetic Nephropathies · United States, Japan, Mexico and more | 2 | Completed | Sep 2014 | 130 |
| NCT01536951Healthy Participants · United States | 1 | Completed | May 2013 | 62 |
| NCT01490632Psoriasis · United States, Canada, Japan and more | 2 | Completed | Dec 2012 | 271 |
| NCT01469013Arthritis, Rheumatoid · Japan | 2 | Completed | Nov 2012 | 145 |
| NCT01398475Arthritis, Rheumatoid · Singapore | 1 | Completed | Sep 2011 | 15 |
| NCT01299285Healthy Volunteers · United States | 1 | Completed | Mar 2011 | 6 |
| NCT01247350Healthy Volunteer · United States | 1 | Completed | Apr 2011 | 34 |
| NCT01185353Arthritis, Rheumatoid · United States, Croatia, Czechia and more | 2 | Completed | Dec 2011 | 301 |
How it is read
Names in the registry
- “Baricitinib”, 53 entries
- “LY3009104”, 5 entries
- “INCB028050”, 3 entries
- “Barcimiant”, 1 entry
- “Baricitinib suspension”, 1 entry
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 13 studies
- Dermatitis, Atopic, 9 studies
- Lupus Erythematosus, Systemic, 4 studies
- COVID-19, 3 studies
- Arthritis, Juvenile, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.